Thymosin treatment of chronic hepatitis B: A placebo‐controlled pilot trial
Milton G. Mutchnick, Henry D. Appelman, H. T. Chung, Emma Aragona, Tej P. Gupta, Glen D. Cummings, Jeanne G. Waggoner, Jay H. Hoofnagle, David A. Shafritz – 1 September 1991 – Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin‐α1 in a prospective, placebo‐controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg.